<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503815</url>
  </required_header>
  <id_info>
    <org_study_id>BLI-800-302</org_study_id>
    <nct_id>NCT00503815</nct_id>
  </id_info>
  <brief_title>BLI-800-302: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy</brief_title>
  <official_title>A Safety and Efficacy Evaluation of BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, parallel, multi-center, single-blind study, comparing BLI-800 to an FDA
      approved bowel preparation in adult subjects undergoing colonoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy - preparation quality using a 4 point scale</measure>
    <time_frame>2-Day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety-preparation related side effects; laboratory analysis</measure>
    <time_frame>30-Day</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Colonoscopy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLI-800</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene glycol 3350 based bowel preparation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Male or female outpatients who are undergoing colonoscopy for a routinely accepted
        indication, including:

        Evaluation of BE results GI bleeding Anemia of unknown etiology Neoplastic disease
        surveillance Endosonography Inflammatory bowel disease Unknown diarrhea or constipation
        etiology Polypectomy Laser therapy Routine Screening

          -  At least 18 years of age

          -  Otherwise in good health, as determined by physical exam and medical history

          -  If female, and of child-bearing potential, is using an acceptable form of birth
             control (hormonal birth control, IUD, double-barrier method, depot contraceptive,
             abstinent, or vasectomized spouse)

          -  Negative urine pregnancy test at screening, if applicable

          -  In the Investigator's judgment, subject is mentally competent to provide informed
             consent to participate in the study

        Exclusion Criteria:

          -  Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal
             obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.

          -  Subjects with impaired consciousness that predisposes them to pulmonary aspiration.

          -  Subjects who are undergoing colonoscopy for foreign body removal and decompression.

          -  Subjects with clinically significant electrolyte abnormalities based on Visit 1
             laboratory results, such as hypernatremia, hyponatremia, hyperphosphatemia,
             hypokalemia, hypocalcemia, dehydration, or those secondary to the use of diuretics or
             angiotensin converting enzyme (ACE) inhibitors.

          -  Subjects with a history of renal or hepatic insufficiency or congestive heart failure.

          -  Subjects who had previous gastrointestinal surgeries

          -  Subjects who are pregnant or lactating, or intending to become pregnant during the
             study.

          -  Subjects of childbearing potential who refuse a pregnancy test.

          -  Subjects who are allergic to any preparation components

          -  Subjects who, in the opinion of the Investigator, should not be included in the study
             for any reason, including inability to follow study procedures.

          -  Subjects who have participated in an investigational clinical, surgical, drug, or
             device study within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D McGowan, B.S.</last_name>
    <role>Study Director</role>
    <affiliation>Braintree Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92869</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <last_update_submitted>December 20, 2007</last_update_submitted>
  <last_update_submitted_qc>December 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2007</last_update_posted>
  <responsible_party>
    <name_title>John McGowan, Clinical Operations Manager</name_title>
    <organization>Braintree Laboratories, Inc.</organization>
  </responsible_party>
  <keyword>colonoscopy</keyword>
  <keyword>bowel preparation</keyword>
  <keyword>prep</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyethylene glycol 3350</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

